Validated microbiological and HPLC methods for the determination of moxifloxacin in Pharmaceutical preparations and human plasma

Brazilian Journal of Microbiology

Volumn 43, Issue 4, 2012, Pages 1291-1301

  Abdelaziz, Ahmed A ^a   Elbanna, Tarek E ^a   Gamaleldeen, Noha M ^a  

^a Tanta University   (Egypt)

Author keywords

HPLC assay; Microbiological assay; Moxifloxacin; Pharmaceutical analysis; Pharmacokinetics

Indexed keywords

EID: 84874346525     PISSN: 15178382     EISSN: 16784405     Source Type: Journal    
DOI: 10.1590/S1517-83822012000400008     Document Type: Article

References (32)

1. Auten, G.M.; Preheim, L.C.; Sookpranee, M.; Bittner, M.J.; Sookpranee, T.; Vibhagool, A. (1991). High-pressure liquid chromatography and microbiological assay of serum ofloxacin levels in adults receiving intravenous and oral therapy for skin infections. Antimicrob Agents Chemother 35, 2558-2561.
2. th ed., (2008). (general notices), Her Majesty's Stationary OfficeApendix XIV, London, UK, p. A323-A329.
3. Balfour, J.A.; Wiseman, L.R. (1999). Moxifloxacin. Drugs 57, 363-373; discussion 374.
4. Ball, P. (2000). The quinolones: history and overview. In: Andriole, V.T. (Ed.), The quinolones, 3rd ed. Academic Press, San Diego, p. 2-24.
5. Bottcher, S.; von Baum, H.; Hoppe-Tichy, T.; Benz, C.; Sonntag, H.G. (2001). An HPLC assay and a microbiological assay to determine levofloxacin in soft tissue, bone, bile and serum. J Pharm Biomed Anal 25,197-203.
6. Clinical Pharmacology, (2009). www.rxlist.com/cgi/generic/moxifloxacin-cp.htm.
7. Djurdjevic, P.; Ciric, A.; Djurdjevic, A.; Stankov, M.J. (2009). Optimization of separation and determination of moxifloxacin and its related substances by RP-HPLC. J Pharm Biomed Anal 50, 117-126.
8. th ed. (2002). Conseil de l'Europe, Strasbourg, 2.7.2., p.160-166.
9. Greco, G.M. (1997). Microbiological assay systems for the analysis of antibiotics in pharmaceutical formulations. (PhD. Dissertation. the State University of New Jersey. USA).
10. Griggs, D.J.; Wise, R. (1989). A simple isocratic high-pressure liquid chromatographic assay of quinolones in serum. J Antimicrob Chemother 24,437-445.
11. Guerra, F.L.; Paim, C.S.; Steppe, M.; Schapoval, E.E. (2005). Biological assay and liquid chromatographic method for analysis of moxifloxacin in tablets. J AOAC Int 88, 1086-1092.
12. Hedaya, M.A. (2007). Basic pharmacokinetics. CRC Press, Boca Raton.
13. Hemanth Kumar, A.K.; Ramachandran, G. (2009). Simple and rapid liquid chromatography method for determination of moxifloxacin in plasma. J Chromatogr B Analyt Technol Biomed Life Sci 877, 1205-1208.
14. Hewitt, W. (2004). Microbiological assay for pharmaceutical analysis: a rational approach. Interpharm/CRC, Boca Raton.
15. Huber, L. (2003). Validation of analytical methods and processes. In: Nash, R.A., Wachter, A.H. (Eds.). Pharmaceutical process validation. 3 ed, New York, USA, p. 507-524.
16. Immanuel, C.; Hemanth Kumar, A.K. (2001). Simple and rapid high- performance liquid chromatography method for the determination of ofloxacin concentrations in plasma and urine. J Chromatogr B Biomed Sci Appl 760, 91-95.
17. Jain, G.K.; Jain, N.; Pathan, S.A.; Akhter, S.; Talegaonkar, S.; Chander, P.; Khar, R.K.; Ahmad, F.J.(2010). Ultra high-pressure liquid chromatographic assay of moxifloxacin in rabbit aqueous humor after topical instillation of moxifloxacin nanoparticles. J Pharm Biomed Anal 52, 110-113
18. Kim, M.K.; Nightingale, C.H. (2000). Pharmacokinetics and pharmacodynamics of the fluoroquinolones. In: Andriole, V.T. (Ed.). The quinolones.3rd ed. Academic Press, San Diego, p. 170-191.
19. Liang, H.; Kays, M.B.; Sowinski, K.M. (2002). Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 772, 53-63.
20. Motwani, S.K.; Chopra, S.; Ahmad, F.J.; Khar, R.K. (2007). Validated spectrophotometric methods for the estimation of moxifloxacin in bulk and pharmaceutical formulations. Spectrochim Acta A Mol Biomol Spectrosc 68, 250-256.
21. Moller, J.G.; Stass, H.; Heinig, R.; Blaschke, G. (1998). Capillary electrophoresis with laser-induced fluorescence: a routine method to determine moxifloxacin in human body fluids in very small sample volumes. J Chromatogr B Biomed Sci Appl 716, 325-334.
22. Nguyen, H.A.; Grellet, J.; Ba, B.B.; Quentin, C.; Saux, M.C. (2004). Simultaneous determination of levofloxacin, gatifloxacin and moxifloxacin in serum by liquid chromatography with column switching. J Chromatogr B Analyt Technol Biomed Life Sci 810, 77-83.
23. Schlech, B.A.; Alfonso, E. (2005). Overview of the potency of moxifloxacin ophthalmic solution 0.5% (VIGAMOX). Surv Ophthalmol 50 Suppl 1, S7-S15.
24. Stass, H.; Dalhoff, A.; Kubitza, D.; Schuhly, U. (1998). Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. Antimicrob Agents Chemother 42, 2060-2065.
25. Tatar Ulu, S. (2007). High-performance liquid chromatography assay for moxifloxacin: pharmacokinetics in human plasma. J Pharm Biomed Anal 43, 320-324.
26. Trindade, M.A.G.; da Silva, G.M.; Ferreira, V.S. (2005). Determination of moxifloxacin in tablets and human urine by square-wave adsorptive voltammetry. Microchemical Journal 81, 209-216.
27. U.S. Food and Drug Administration, Guidance for Industry, Bioanalytical Method Validation, (2001). U.S. Department of Health and Human Services, Center for Drug Evaluation and Research (CDER), Centre of Veterinary Medicine (CVM), Rockville, USA Internet://www.fda.gov/cvm.
28. Ulu, S.T. (2009). Spectrofluorimetric determination of fluoroquinolones in pharmaceutical preparations. Spectrochim Acta A Mol Biomol Spectrosc 72, 138-143.
29. US Pharmacopoeia & National Formulary (2009). Second supplement, Moxifloxacin, Official Monographs, USP32-NF27, US Pharmacopeial Convention Inc., Rockville, p. 4264-4267.
30. US Pharmacopoeia & National Formulary (2009). <81> Antibiotics- Microbial assays, USP32-NF27, US Pharmacopeial Convention Inc., Rockville, p. 86-93.
31. Wagenlehner, F.M.; Kees, F.; Weidner, W.; Wagenlehner, C.; Naber, K.G. (2008). Concentrations of moxifloxacin in plasma and urine, and penetration into prostatic fluid and ejaculate, following single oral administration of 400 mg to healthy volunteers. Int J Antimicrob Agents 31, 21-26.
32. Zhanel, G.G.; Noreddin, A.M. (2001). Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections. Curr OpinPharmacol 1, 459-463